End Stage Renal Disease. End stage renal disease
Conditions
Interventions
Intervention 1: Intervention group: Selenium 200 mg receiving group as oral capsule from 20th Century Pharmaceutical Company for 3 months daily capsule version. Intervention 2: Control group: The cont
Sponsors
Zahedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Hemodialysis duration more than 6 months
Exclusion criteria
Exclusion criteria: Sensitivity to selenium Selenium consumption over the past 3 months Thyroid disease needs treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in serum free T4. Timepoint: At the beginning of the intervention and 12 weeks after the start of the intervention. Method of measurement: Chemi Luminescence.;Changes in serum free T4. Timepoint: At the beginning of the intervention and 12 weeks after the start of the intervention. Method of measurement: Chemi Luminescence.;Changes in TSH level. Timepoint: At the beginning of the intervention and 12 weeks after the start of the intervention. Method of measurement: Chemi Luminescence.;Changes in rT3 level. Timepoint: At the beginning of the intervention and 12 weeks after the start of the intervention. Method of measurement: Chemi Luminescence.;Changes in Selenium level. Timepoint: At the beginning of the intervention and 12 weeks after the start of the intervention. Method of measurement: atomic absorption spectrophotometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Adineh
Zahedan University of Medical Sciences
Outcome results
None listed